Eugenia Nikolsky

Summary

Affiliation: Cardiovascular Research Foundation
Country: USA

Publications

  1. doi request reprint Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA
    Am J Cardiol 104:22C-9C. 2009
  2. doi request reprint Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 54:1293-302. 2009
  3. doi request reprint Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial)
    Kenichi Tsujita
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 105:1385-94. 2010
  4. doi request reprint A risk score to predict bleeding in patients with acute coronary syndromes
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 55:2556-66. 2010
  5. doi request reprint Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial In
    Adam J Saltzman
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    JACC Cardiovasc Interv 4:1011-9. 2011
  6. doi request reprint Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial)
    Kenji Goto
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 108:1387-94. 2011
  7. doi request reprint Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JACC Cardiovasc Interv 2:624-32. 2009
  8. doi request reprint Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY)
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:748-57. 2009
  9. doi request reprint Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent int
    Roxana Mehran
    Department of Cardiology, Mount Sinai Medical Center, New York, New York, USA
    JACC Cardiovasc Interv 4:654-64. 2011
  10. ncbi request reprint Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial)
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 99:1055-61. 2007

Collaborators

Detail Information

Publications61

  1. doi request reprint Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA
    Am J Cardiol 104:22C-9C. 2009
    ..We discuss the risk of GIB in patients treated with different antiplatelet and antithrombotic medications and their combinations, factors associated with GIB, and its optimal management and prevention...
  2. doi request reprint Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 54:1293-302. 2009
    ..We assessed the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute coronary syndromes (ACS)...
  3. doi request reprint Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial)
    Kenichi Tsujita
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 105:1385-94. 2010
    ..Paradoxically, in this post hoc analysis, the reductions in major bleeding and mortality in ST elevation myocardial infarction afforded by bivalirudin occurred primarily in patients without baseline anemia...
  4. doi request reprint A risk score to predict bleeding in patients with acute coronary syndromes
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 55:2556-66. 2010
    ..The aim of this study was to develop a practical risk score to predict the risk and implications of major bleeding in acute coronary syndromes (ACS)...
  5. doi request reprint Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial In
    Adam J Saltzman
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    JACC Cardiovasc Interv 4:1011-9. 2011
    ..This study sought to investigate the impact of chronic kidney disease (CKD) in patients undergoing percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) with different antithrombotic strategies...
  6. doi request reprint Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial)
    Kenji Goto
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 108:1387-94. 2011
    ..Bivalirudin monotherapy compared to UFH plus a GPI decreased major bleeding regardless of smoking status but may have different effects on individual components of ischemic events...
  7. doi request reprint Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JACC Cardiovasc Interv 2:624-32. 2009
    ..We sought to determine the relationship between red blood cell (RBC) transfusion and clinical outcomes in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)...
  8. doi request reprint Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY)
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:748-57. 2009
    ....
  9. doi request reprint Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent int
    Roxana Mehran
    Department of Cardiology, Mount Sinai Medical Center, New York, New York, USA
    JACC Cardiovasc Interv 4:654-64. 2011
    ..This study sought to develop a risk score predictive of bleeding in patients undergoing percutaneous coronary intervention (PCI) and to investigate the impact of bleeding on subsequent mortality...
  10. ncbi request reprint Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial)
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 99:1055-61. 2007
    ..03, 95% CI 1.00 to 1.06, p = 0.055) at 1 year. In conclusion, a higher baseline platelet count in patients with AMI is a powerful independent predictor of death and reinfarction within the first year after primary PCI...
  11. doi request reprint Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials
    Jacob A Doll
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, USA
    J Interv Cardiol 22:453-9. 2009
    ..The lack of a specific counteragent to bivalirudin may complicate the management of patients with coronary artery (CA) perforation during percutaneous coronary intervention (PCI)...
  12. ncbi request reprint An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY 10022, USA
    J Invasive Cardiol 19:208-13. 2007
    ..We evaluated short-term prognosis and resource utilization of consecutive patients treated with percutaneous coronary intervention (PCI) as a function of fluoroscopy time...
  13. ncbi request reprint A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation
    Roxana Mehran
    Cardiovascular Research Foundation, Columbia University Medical Center, New York, New York 10022, USA
    J Am Coll Cardiol 44:1393-9. 2004
    ..We sought to develop a simple risk score of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI)...
  14. doi request reprint 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents
    Adriano Caixeta
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 54:894-902. 2009
    ..Five-year clinical follow-up has been scheduled per protocol by the 4 Cypher (Cordis/Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) versus bare-metal stent (BMS) randomized trials...
  15. doi request reprint Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
    Roxana Mehran
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA
    Lancet 374:1149-59. 2009
    ..Here, we assess whether these initial benefits were maintained at 1 year of follow-up...
  16. ncbi request reprint Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction
    Eugenia Nikolsky
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 96:474-81. 2005
    ..0% vs 3.9%, p = 0.03) in patients who developed thrombocytopenia. In conclusion, thrombocytopenia that develops after primary PCI for AMI, although uncommon, is associated with increased hemorrhagic complications and decreased survival...
  17. doi request reprint Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in
    Martin B Leon
    Columbia University Medical Center, New York, New York 10032, USA
    JACC Cardiovasc Interv 3:1043-50. 2010
    ..The increased frequency of very late (>1 year) stent thrombosis (VLST) has raised concerns with regard to the safety of sirolimus-eluting stents and paclitaxel-eluting stents (PES)...
  18. doi request reprint Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial
    Kenji Goto
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    JACC Cardiovasc Interv 4:769-77. 2011
    ....
  19. doi request reprint Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium
    Martin B Leon
    Columbia University Medical Center, New York, New York 10032, USA
    J Am Coll Cardiol 57:253-69. 2011
    ..To make these consensus definitions accessible to all stakeholders in TAVI clinical research through a peer reviewed publication, on behalf of the public health...
  20. ncbi request reprint Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention
    Eugenia Nikolsky
    Cardiovascular Research Foundation, and Lenox Hill Heart and Vascular Institute, New York, New York, USA
    Am J Cardiol 94:300-5. 2004
    ..Contrast-induced nephropathy was among the independent predictors of a 1-year mortality rate (OR 2.75, p <0.001)...
  21. ncbi request reprint Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York, USA
    Kidney Int 67:706-13. 2005
    ..The relationship between low hematocrit and contrast-induced nephropathy has not been investigated...
  22. doi request reprint Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis
    George D Dangas
    Mount Sinai Medical Center, New York, NY, USA
    J Am Coll Cardiol 57:2309-16. 2011
    ..We investigated the outcomes of switching to bivalirudin after initial administration of heparin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention...
  23. ncbi request reprint Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, NY 10022, USA
    Am J Cardiol 93:1536-9. 2004
    ..These 2 conditions are associated with adverse in-hospital and 1-year outcomes and independently predict early and 1-year mortality...
  24. doi request reprint Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents
    Eugenia Nikolsky
    Columbia University Medical Center, Center for Interventional Vascular Therapy and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Catheter Cardiovasc Interv 71:896-906. 2008
    ..We assessed the outcomes in diabetic patients undergoing percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SES) as a function of treatment with glycoprotein (GP) IIb/IIIa inhibitors...
  25. doi request reprint Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
    Adriano Caixeta
    Cardiovascular Research Foundation, New York, NY, USA
    Am Heart J 161:298-306.e1. 2011
    ..The aim of the study was to investigate the incidence and clinical consequences of acquired thrombocytopenia in patients with acute coronary syndromes (ACS) in the ACUITY trial...
  26. doi request reprint Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic End
    Martin B Leon
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:1208-18. 2009
    ..The aim of this study was to assess, after 2 years of follow-up, the safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent (ZES) compared with a paclitaxel-eluting stent (PES) in patients with native coronary lesions...
  27. ncbi request reprint Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions
    Ioannis Iakovou
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, New York 10022, USA
    Am J Cardiol 93:346-9. 2004
    ..5%) were aged > or =75 years (253 procedures, 430 lesions). Very elderly patients (> or =75 years) had similar in-hospital outcomes but a higher hemorrhagic stroke rate than patients aged <75 years...
  28. ncbi request reprint Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables
    George Dangas
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, New York, USA
    Am J Cardiol 95:13-9. 2005
    ..22 to 2.60). Thus, regardless of the presence of CKD, baseline characteristics and periprocedural hemodynamic parameters predict CIN, and this complication is associated with worse in-hospital and 1-year outcomes...
  29. ncbi request reprint Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach
    Eugenia Nikolsky
    Cardiovascular Research Foundation, Columbia University Medical Center, Herbert Irving Pavilion, 5th Floor, 161 Fort Washington Avenue, New York, NY 10032, USA
    Eur Heart J 28:1936-45. 2007
    ..Major bleeding after percutaneous coronary intervention (PCI) is an independent risk factor for early and late mortality. We developed and validated a risk score predictive of major bleeding after PCI using the femoral approach...
  30. doi request reprint Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic rena
    Roxana Mehran
    Center for Interventional Vascular Therapies, Columbia University Medical Center, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:415-21. 2009
    ....
  31. ncbi request reprint Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials
    Jeffrey W Moses
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 47:2164-71. 2006
    ....
  32. ncbi request reprint Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis
    Eugenia Nikolsky
    Cardiovascular Research Foundation and the Lenox Hill Heart and Vascular Institute, New York, New York 10022, USA
    J Am Coll Cardiol 44:1200-9. 2004
    ..This study was designed to assess the safety of arteriotomy closure devices (ACDs) versus mechanical compression by meta-analysis in patients undergoing percutaneous transfemoral coronary procedures...
  33. ncbi request reprint Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction
    Eugenia Nikolsky
    Columbia University Medical Center, New York, NY, USA
    Am Heart J 151:168-75. 2006
    ..We therefore sought to investigate the impact of body mass index (BMI) in patients with AMI undergoing primary PCI...
  34. doi request reprint Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
    Yanai Ben-Gal
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    JACC Cardiovasc Interv 3:1059-67. 2010
    ....
  35. ncbi request reprint Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions
    Eugenia Nikolsky
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10022, USA
    Am J Cardiol 94:1023-7. 2004
    ..8% vs 3.5%). After adjustment for potential confounders, baseline hematocrit remained a significant predictor of a 1-year mortality rate (hazard ratio 0.93 per 1% increase in hematocrit, 95% confidence interval 0.91 to 0.95)...
  36. ncbi request reprint Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 44:547-53. 2004
    ..We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI)...
  37. ncbi request reprint Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score
    Amir Halkin
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 45:1397-405. 2005
    ..We sought to develop a simple risk score for predicting mortality after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)...
  38. ncbi request reprint An Internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation
    Roxana Mehran
    Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 150:1171-6. 2005
    ..Heparin coating is an attractive alternative to counterbalance intrinsic stent thrombogenicity and to decrease the incidence of stent thrombosis...
  39. ncbi request reprint Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial
    Jeffrey W Moses
    Columbia University Medical Center, New York, New York, USA
    J Am Coll Cardiol 45:1165-71. 2005
    ..We sought to investigate the outcomes of paclitaxel-eluting stent implantation in patients with unstable angina or non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI)...
  40. ncbi request reprint Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study
    Ioannis Iakovou
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, New York 10022, USA
    J Am Coll Cardiol 42:1900-5. 2003
    ..We sought to determine the impact of aggressive stent expansion on creatine kinase-MB isoenzyme (CK-MB) release and clinical restenosis...
  41. ncbi request reprint Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients >or=75 years of age versus those <75 years of age
    Ioannis Iakovou
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, New York 10022, USA
    Am J Cardiol 92:1083-6. 2003
    ..5% were >or=75 years of age. Compared with patients <75 years old, those >or=75 years of age had similar procedural and in-hospital outcomes but significantly higher rates of hemorrhagic stroke (0.08% vs 1.2%, p <0.001)...
  42. pmc Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, 161 Fort Washington Avenue, New York, NY 10032, USA
    Eur Heart J 30:1457-66. 2009
    ..Both MI and major bleeding predict 1-year mortality in patients presenting with acute coronary syndrome (ACS). However, the risk of each of these events on the magnitude and timing of mortality has not been well studied...
  43. doi request reprint Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS
    Diaa A Hakim
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA
    Am Heart J 161:391-6. 2011
    ..Thrombocytopenia (TP) is a common abnormality in patients presenting with acute coronary syndrome. Whether baseline TP has any influence on the outcome of patients treated with primary angioplasty for acute myocardial infarction is unknown...
  44. pmc Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
    Martin B Leon
    Columbia University Medical Center, Center for Interventional Vascular Therapy, 173 Fort Washington Avenue, Heart Center, New York, NY 10032, USA
    Eur Heart J 32:205-17. 2011
    ..To make these consensus definitions accessible to all stakeholders in TAVI clinical research through a peer reviewed publication, on behalf of the public health...
  45. ncbi request reprint Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial)
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    Am J Cardiol 95:709-15. 2005
    ..Paclitaxel-eluting stents attenuate the increased risk associated with obesity, such that the intermediate-term prognosis after percutaneous coronary intervention is independent of weight...
  46. ncbi request reprint Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial
    Eugenia Nikolsky
    Columbia University Medical Center, New York, NY, USA
    EuroIntervention 5:417-24. 2009
    ..Whether GuardWire is beneficial in patients with AMI in certain territories of the coronary circulation is unknown...
  47. ncbi request reprint Gender-specific outcomes after sirolimus-eluting stent implantation
    Emilia Solinas
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 50:2111-6. 2007
    ..We examined the impact of gender on outcomes of patients undergoing percutaneous coronary intervention using sirolimus-eluting stents (SES)...
  48. ncbi request reprint Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions
    Eugenia Nikolsky
    Cardiovascular Research Foundation and the Lenox Hill Heart and Vascular Institute, New York, New York 10022, USA
    J Endovasc Ther 11:60-70. 2004
    ..To determine the impact of symptomatic peripheral arterial disease (PAD) on clinical outcomes in patients treated with percutaneous coronary interventions (PCI)...
  49. ncbi request reprint Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)
    Ricardo A Costa
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10022, USA
    Am J Cardiol 95:113-6. 2005
    ..There was 1 in-stent and 1 in-segment (proximal edge) restenosis in the metallic stent group. There was no stent thrombosis or aneurysm formation at follow-up in either group...
  50. ncbi request reprint Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial
    Jeffrey W Moses
    The Columbia University Medical Center, Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 98:1455-60. 2006
    ..6%. In conclusion, use of the 2.25-mm sirolimus-eluting Bx Velocity stent was safe and provided favorable 6-month clinical outcomes. Use of multiple stents (in longer lesions) was an independent predictor of in-lesion restenosis...
  51. ncbi request reprint Vascular closure devices: a review of their use after invasive procedures
    Zoran Lasic
    Lenox Hill Hospital and Cardiovascular Research Foundation, New York 10022, USA
    Am J Cardiovasc Drugs 5:185-200. 2005
    ....
  52. doi request reprint A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial
    Martin B Leon
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 55:543-54. 2010
    ....
  53. doi request reprint SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 158:520-526.e2. 2009
    ..We therefore designed a large-scale randomized trial without angiographic follow-up to further assess the differences between these 2 stent platforms...
  54. ncbi request reprint Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    Semin Thromb Hemost 30:305-14. 2004
    ..Optimal dosing regimens for argatroban, lepirudin, and bivalirudin should be further established in PCI patients...
  55. ncbi request reprint Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients
    Zoran Lasic
    Department of Interventional Cardiology, Lenox Hill Hospital, 100 East 77th Street, New York, NY 10021, USA
    J Invasive Cardiol 16:356-8. 2004
    ..This study found that the new Angio-Seal STS Platform device can secure hemostasis after PCI in a safe and effective manner similar to the old device. The new platform is easier for the operator and for the patients...
  56. ncbi request reprint Prevention and treatment of contrast-associated nephropathy in interventional cardiology
    Adriano Caixeta
    Data Coordinating and Analysis Center, Cardiovascular Research Foundation, New York, NY 10022, USA
    Curr Cardiol Rep 11:377-83. 2009
    ..Despite the remaining uncertainty regarding the degree of nephrotoxicity produced by various contrast agents, nonionic low-osmolar contrast media may be preferred in patients at high risk for CIN...
  57. ncbi request reprint PCI options in heparin-induced thrombocytopenia
    George Dangas
    Cardiovascular Research Foundation, Lenox Hill Heart Vascular Institute, New York, NY 10022, USA
    J Invasive Cardiol 15:622-3. 2003
  58. ncbi request reprint Images in cardiology: A saphenous vein graft aneurysm fistula causing pulmonary artery dissection
    Zoran Lasic
    Lenox Hill Heart and Vascular Institute of New York, New York, USA
    Clin Cardiol 27:450. 2004
  59. ncbi request reprint Understanding the consequences of contrast-induced nephropathy
    Eugenia Nikolsky
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, New York, USA
    Rev Cardiovasc Med 4:S10-8. 2003
    ..The authors also present the risk score they developed to help clinicians identify patients with different responses to contrast exposure...
  60. pmc The next revolution: percutaneous aortic valve replacement
    Martin B Leon
    Professor of Medicine, Columbia University College of Physicians and Surgeons, Associate Director, Center for Interventional Vascular Therapy, New York Presbyterian Hospital Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, USA
    Rambam Maimonides Med J 1:e0016. 2010
    ..The results of randomized comparison of TAVI with AVR among high-risk patients with AS for whom surgery is a viable option are eagerly awaited to provide further evidence on the applicability of TAVI in these patients. ..
  61. ncbi request reprint Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function
    Eugenia Nikolsky
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY, USA
    Rev Cardiovasc Med 4:S7-S14. 2003
    ..This article focuses on the incidence, pathogenesis, risk factors, and prognosis of radiocontrast nephropathy and provides important insights on its prevention...